Compare Citius Pharmaceuticals Inc (CTXR) vs e l f Beauty Inc (ELF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs e l f Beauty Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while e l f Beauty Inc trades at $94.89 (market cap $5.62B). The key difference: e l f Beauty Inc is far larger — about 300.1× Citius Pharmaceuticals Inc's market cap, and e l f Beauty Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | ELF | |
|---|---|---|
Market Cap | $18.73M | $5.62B |
Sector | Health | Technology |
52-Week High | $1.82 | $146.67 |
52-Week Low | $0.48 | $49.57 |
Enterprise Value | $14.95M | $6.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
ELF trades at $98.49, up 6.69% in 24 hours, near its 52-week high. The stock exhibits a bullish technical trend with strong support at $93 and resistance at $101. Recent Q2 2026 earnings beat expectations with EPS of $1.75 versus $0.71 expected, driven by 36% revenue growth and the Rhode acquisition. The company raised fiscal 2027 guidance, reflecting robust demand and international expansion.
Outlook remains positive due to consistent sales growth and strategic initiatives, but risks include high valuation (P/E 97.18) and reliance on acquisitions for growth. The stock offers growth potential but faces margin pressure from increased investments and competitive dynamics in the beauty sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About e l f Beauty Inc
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →
